This program, scheduled for November 19, 2020, has been cancelled. We look forward to hearing Dr. Castrillon’s talk: "Endometrial cancer: genetic models and translational studies” at a later date.
Diego H. Castrillon, MD, PhD
University of Texas Southwestern Medical Center, Department of Pathology
Endometrial cancer: genetic models and translational studies
Dr. Diego H. Castrillon is a Professor of Pathology and Obstetrics & Gynecology at UT Southwestern and holds the Vernie A. Stembridge, M.D., Distinguished Chair in Pathology. He serves as the Director of the research arm of the Department of Pathology. In addition to directing a research laboratory devoted to the study of endometrial cancer, he is a practicing pathologist in the Gynecologic Pathology Division, specializing in the diagnosis of diverse obstetrical and gynecologic conditions.
Dr. Castrillon’s research and clinical focus centers around the pathophysiology and molecular genetics of endometrial cancer. Endometrial cancer is the 4th most common malignancy in women, but is perhaps the most underfunded common malignancy relative to its clinical impact, number of deaths, and years-of-life-lost. His laboratory has developed novel tools and approaches for the development of genetically-engineered mouse models of endometrial cancer, which can serve as unique tools to reveal essential cellular and organismal biology and illuminate mechanisms—such as genome instability—underlying tumorigenesis. He also studies early endometrial cancer progression and is working towards the identification and validation of biomarkers for very early precancers, which can be difficult to diagnose in limited biopsies.
Dr. Castrillon received an S.B. in Life Sciences at M.I.T., where he worked for four years in the laboratory Dr. Gerry Fink, followed by M.D. and Ph.D. degrees from UT Southwestern. He completed a residency in surgical pathology and a one year clinical fellowship in Obstetric and Gynecologic Pathology at Brigham & Women’s Hospital, and a postdoctoral research fellowship at the Dana Farber Cancer Institute in cancer genetics in the laboratory of Dr. Ron DePinho. He joined the faculty of UT Southwestern In 2003. Dr. Castrillon is an elected member of the American Society of Clinical Investigation and a member of the International Society of Gynecologic Pathologists, and serves as a consulting editor for the Journal of Clinical Investigation and the International Journal of Gynecologic Pathology.
The Judith Ann Lippard Memorial Lecture was established in 2014 in memory of Judy Lippard, the wife of Stephen J. Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT. Judy died of endometrial cancer on September 9, 2013. Steve, Josh, and Alex Lippard, together with countless friends, students, and colleagues created the lecture to honor Judy’s memory and celebrate her remarkable love of life.
The creation of the Judith Ann Lippard Lecture was inspired by a similar lecture, created in 1974 in memory of Judy’s and Steve’s eldest son, Andrew, who died from a neurological disorder at age 7. Over time, the Andrew Mark Lippard Lecture at Columbia University has become one of the preeminent neurology lectures in the world.
The Judith Ann Lippard Lecture brings together the most innovative minds in cancer research from a variety of disciplines—biology, chemistry, engineering, clinical medicine—and features individuals whose research has the possibility to change the face of women's cancers. The Lippard Lecture also unites two extraordinary cancer centers—MIT’s Koch Institute and the Massachusetts General Hospital Cancer Center. In addition to the formal lecture at MIT, the honoree delivers Grand Rounds at MGH, and spends time with trainees, researchers, and physician-scientists at both institutions, thus inspiring the best and brightest young minds to advance cancer therapies.
Tyler Jacks, PhD
Stephen J. Lippard, PhD, ex officio
Daniel A. Haber, MD, PhD
Jonathan Rosand, MD, MSc
Phillip A. Sharp, PhD
To join the Lippard family in celebrating Judy's life and legacy, please contact Lisa Schwarz, Managing Director of Development, Koch Institute for Integrative Cancer Research at MIT: 617-324-7399; firstname.lastname@example.org, or give online.